A novel chimeric antigen receptor T-cell therapy targeting CD84 for the treatment of acute myeloid and T-cell lymphoblastic leukemias – New Study
A novel chimeric antigen receptor T-cell therapy targeting CD84 for the treatment of acute myeloid and T-cell lymphoblastic leukemias
Summary
A novel CAR-T cell therapy targeting CD84 is showing promise for treating acute myeloid leukemia (AML) and T-cell lymphoblastic leukemia (T-ALL). CD84, a protein found on leukemia cells, serves as the target for these engineered T-cells. Preclinical studies demonstrate that CD84-CAR-T cells effectively eliminate leukemia cells in vitro and in vivo. This approach offers a potential solution to overcome limitations of existing treatments, especially for patients with relapsed or refractory disease. Further research and clinical trials are crucial to assess the safety and efficacy of CD84-CAR-T cell therapy in human patients with these aggressive leukemias.
Read more…
Credits: Source
This post is part of “Science/Immunology News”, Follow for more…!!!
